Delcath Systems to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

View printer-friendly version

NEW YORK, NY / ACCESSWIRE / February 6, 2017 / Delcath Systems, Inc. (NASDAQ - DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announced today that it will be presenting at the 2nd annual Disruptive Growth & Healthcare Conference on Wednesday, February 15, 2017 at 11:15 AM EST. Delcath President & Chief Executive Officer Dr. Jennifer K. Simpson will be presenting, as well as meeting with investors.

The 2017 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.

A webcast of Dr. Simpson’s presentation will be available at http://www.investorcalendar.com/event/11176

News Compliments of Accesswire

About Delcath Systems

Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS system for the treatment of primary liver cancer (HCC) and intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

For those interested in attending, please visit www.DisruptNYC.com for more information.

Contact:
Tristan Traywick
Managing Director
CORE IR
377 Oak Street
Garden City, NY 11530
Tel: 206-946-1903 
Email: tt@coreir.com
www.coreir.com